{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:50:59Z","timestamp":1782208259750,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"DOI":"10.7759\/cureus.111344","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:22:56Z","timestamp":1782206576000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond the Colon: Acute Hemolysis Associated With Etrasimod Therapy"],"prefix":"10.7759","author":[{"given":"Sohaib","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saud","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vargas Carranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Usman","family":"Mumtaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Delzoppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-673600586-X","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"8","author":"Sandborn WJ","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al.. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023, 8:1159-71. 10.1016\/S0140-673600586-X","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study","volume":"15","author":"Vermeire S","year":"2021","unstructured":"Vermeire S, Chiorean M, Pan\u00e9s J, et al.. Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study. J Crohns Colitis. 2021, 15:950-9. 10.1093\/ecco-jcc\/jjab016","journal-title":"J Crohns Colitis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn WJ","year":"2020","unstructured":"Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al.. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020, 158:550-61. 10.1053\/j.gastro.2019.10.035","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S391706","article-title":"Therapeutic potential of etrasimod in the management of moderately-to-severely active ulcerative colitis: evidence to date","volume":"17","author":"Glassner K","year":"2024","unstructured":"Glassner K, Fan C, Irani M, Abraham BP. Therapeutic potential of etrasimod in the management of moderately-to-severely active ulcerative colitis: evidence to date. Clin Exp Gastroenterol. 2024, 17:337-45. 10.2147\/CEG.S391706","journal-title":"Clin Exp Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/trf.70222","article-title":"Drug-induced hemolytic anemia due to ceftriaxone in a patient with recently identified alloantibodies: a diagnostic challenge","volume":"4","author":"Balusu K","year":"2026","unstructured":"Balusu K, Ehsanullah SU, Olejniczak J, Bensing K, Pugh T, Puca K, Choate J. Drug-induced hemolytic anemia due to ceftriaxone in a patient with recently identified alloantibodies: a diagnostic challenge. Transfusion. 2026, 4:23-5. 10.1111\/trf.70222","journal-title":"Transfusion"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009801","article-title":"Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study","volume":"8","author":"Maquet J","year":"2024","unstructured":"Maquet J, Lafaurie M, Michel M, Lapeyre-Mestre M, Moulis G. Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study. Blood Adv. 2024, 8:817-26. 10.1182\/bloodadvances.2023009801","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.73","article-title":"Drug-induced immune hemolytic anemia","volume":"4","author":"Garratty G","year":"2009","unstructured":"Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009, 4:73-9. 10.1182\/asheducation-2009.1.73","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.04.004","article-title":"The changing spectrum of drug-induced immune hemolytic anemia","volume":"42","author":"Arndt PA","year":"2005","unstructured":"Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol. 2005, 42:137-44. 10.1053\/j.seminhematol.2005.04.004","journal-title":"Semin Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000181","article-title":"Ceftriaxone-induced hemolytic anemia: case report and review of literature","volume":"37","author":"Northrop MS","year":"2015","unstructured":"Northrop MS, Agarwal HS. Ceftriaxone-induced hemolytic anemia: case report and review of literature. J Pediatr Hematol Oncol. 2015, 37:e63-6. 10.1097\/MPH.0000000000000181","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2016.12.006","article-title":"Autoimmune cytopenias associated with inflammatory bowel diseases: insights from a multicenter retrospective cohort","volume":"49","author":"Uzzan M","year":"2017","unstructured":"Uzzan M, Galicier L, Gornet JM, et al.. Autoimmune cytopenias associated with inflammatory bowel diseases: insights from a multicenter retrospective cohort. Dig Liver Dis. 2017, 49:397-404. 10.1016\/j.dld.2016.12.006","journal-title":"Dig Liver Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/497010-beyond-the-colon-acute-hemolysis-associated-with-etrasimod-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:22:57Z","timestamp":1782206577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/497010-beyond-the-colon-acute-hemolysis-associated-with-etrasimod-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.111344","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}